Taizhou ZhiLiang Medical Laboratory, which obtained its Medical Institution Practice License in July 2018, is a comprehensive laboratory integrating DNA and RNA nucleic acid testing for various pathogens and routine clinical tests. The laboratory is located in Taizhou, China Medical City, covering an area of over 1,000 square meters. It is equipped with a state-of-the-art AutoSAT fully automated nucleic acid detection and analysis system, utilizing real-time fluorescence isothermal amplification technology (Simultaneous Amplification and Testing, SAT technology).

ZhiLiang Medical Molecular Laboratory not only meets the demand for viral DNA testing of infectious pathogens but also has achieved significant results in SAT technology testing services. These include RNA isothermal amplification testing for various pathogens/genetic materials, such as reproductive health (Chlamydia trachomatis, Neisseria gonorrhoeae, Ureaplasma urealyticum, Mycoplasma genitalium), respiratory system (Mycoplasma pneumoniae, Mycobacterium tuberculosis complex, Influenza A), and hand, foot, and mouth disease (Enterovirus 71, Coxsackievirus A16, and other enteroviruses).

ZhiLiang Medical Routine Clinical Laboratory has developed testing for a range of parameters, including blood glucose series, blood lipid series, liver function series, kidney function series, myocardial enzyme spectrum series, electrolyte series, and urinary kidney function tests. The laboratory provides results within 12 hours and participates annually in inter-laboratory quality assessments organized by the National Health Ministry, Jiangsu Province Clinical Testing Center, Shanghai Clinical Testing Center, and others. This ensures that the laboratory meets the clinical demand for biochemical, chemiluminescence, blood cell, and other testing. Additionally, the laboratory holds HIV testing accreditation and is capable of conducting human immunodeficiency virus antibody testing, providing comprehensive support for clinical diagnosis and treatment.

Precision medicine is the future direction of healthcare, and the starting point of medical treatment is diagnosis. Only accurate diagnoses can lead to precise treatments. With the advancement of molecular testing technologies, an increasing number of pathogen detections can achieve precise diagnoses. Molecular testing technologies, primarily represented by DNA and RNA detection, are significant because RNA only exists in living pathogens. Therefore, RNA-targeted diagnostic technologies can reflect the activity status of pathogens, and they can be used for monitoring treatment efficacy, guiding clinical precision medication, and achieving the goal of precision medicine.

We aim to transform advanced medical research achievements into clinical application services through ZhiLiang Laboratory, significantly enhancing clinical healthcare standards and diagnostic efficacy. With a strong sense of civic responsibility, we serve society and protect the well-being of the people with compassion. ZhiLiang Medical is committed to actively contributing to the realization of the Healthy China Dream through practical actions.